Pharming Presents Positive Phase II Topline Data For Leniolisib

By Reuters News

Oct 14 (Reuters) - Pharming Group N.V. PHAR.AS:

  • PRESENTS POSITIVE PHASE II TOPLINE DATA FOR LENIOLISIB IN GENETIC PIDS WITH IMMUNE DYSREGULATION AT ESID 2026

  • LENIOLISIB WELL-TOLERATED WITH BENEFITS IN IMMUNE DYSREGULATION MEASURES

  • MEAN SPLEEN VOLUME REDUCTION OF 26.4% IN PHASE II LENIOLISIB TRIAL

  • IMPROVEMENT IN LIVER STIFFNESS OBSERVED IN PHASE II LENIOLISIB TRIAL

  • MEAN LYMPH NODE LESION SIZE REDUCTION OF 33.7% IN PHASE II LENIOLISIB TRIAL

  • MEAN DLCO INCREASED BY 8.0% IN PHASE II LENIOLISIB TRIAL

  • ALL PHASE II LENIOLISIB STUDY COMPLETERS ENROLLED IN THREE-YEAR EXTENSION STUDY

  • LENIOLISIB WAS GENERALLY WELL-TOLERATED ACROSS ALL 4 GENOTYPES

  • TOPLINE RESULTS FROM SEPARATE PHASE II TRIAL IN CVID EXPECTED IN NOVEMBER

Further company coverage: PHAR.AS

Capital.com is an execution-only brokerage platform and the content provided on the Capital.com website is intended for informational purposes only and should not be regarded as an offer to sell or a solicitation of an offer to buy the products or securities to which it applies. No representation or warranty is given as to the accuracy or completeness of the information provided.

The information provided does not constitute investment advice nor take into account the individual financial circumstances or objectives of any investor. Any information that may be provided relating to past performance is not a reliable indicator of future results or performance.

To the extent permitted by law, in no event shall Capital.com (or any affiliate or employee) have any liability for any loss arising from the use of the information provided. Any person acting on the information does so entirely at their own risk.

Any information which could be construed as “investment research” has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such is considered to be a marketing communication.